Trabectedine (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 159 | Xeroderma pigmentosum | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022968-13-BE (EUCTR) | 16/03/2011 | 04/01/2011 | Study of the medicinal product Trabectedin in Patients with AdvancedBreast Carcinoma. | Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG) | Advanced Breast Carcinoma MedDRA version: 14.0;Level: LLT;Classification code 10006204;Term: Breast carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion. INN or Proposed INN: trabectedine Trade Name: Yondelis 1 mg powder for concentrate for solution for infusion. INN or Proposed INN: trabectedine | Pharma Mar, S.A. Sociedad Unipersonal | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Spain;Belgium |